The overall ratings of three Pharmaceutical stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Medicis Pharmaceutica (NYSE:MRX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Medicis Pharmaceutical provides pharmaceuticals focusing on the treatment of dermatological, pediatric, and podiatric conditions, as well as aesthetics medicine. To get an in-depth look at MRX, get Portfolio Grader’s complete analysis of MRX stock.

This week, Simcere Pharmaceutical Group (NYSE:SCR) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Simcere Pharmaceutical Group manufactures and supplies branded generic pharmaceuticals to the China market. The stock gets F’s in Earnings Growth, Earnings Revisions, and Earnings Surprise.

For more information, get Portfolio Grader’s complete analysis of SCR stock.

Zogenix (NASDAQ:ZGNX) gets weaker ratings this week as last week’s C drops to a D. Zogenix is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The stock gets F’s in Cash Flow and Sales Growth. For a full analysis of ZGNX stock, visit Portfolio Grader.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.